Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic
Oral Biologics Specialist Using Celltrion’s CT-P43 Candidate Under License
As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.
